Peng Han

Peng Han

Auto-generated profile, based on publicly available information

Peng Han

Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, 210008 Nanjing, Jiangsu, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
PHPeng Han
Peng Han
ZQZhiqiang Qin
Zhiqiang Qin
JTJingyuan Tang
Jingyuan Tang
ZXZhen Xu
Zhen Xu
RLRan Li
Ran Li
WZWei Zhang
Wei Zhang
Acute kidney injury (AKI) induced by ischemia‐reperfusion is a critical conundrum in many clinical settings. Here, this study aimed to determine whether and how RTA‐408, a novel oleanane triterpenoid, could confer protection against renal ischemia‐reperfusion injury (IRI) in male mice. Mice treated with RTA‐408 undergoing unilateral ischemia followed by contralateral nephrectomy had improved renal function and histological outcome, as well as decreased apoptosis, ROS production, and oxidative injury marker compared with vehicle‐treated mice. Also, we had found that RTA‐408 could strengthen the total antioxidant capacity by increasing Nrf2 nuclear translocation and subsequently increased Nrf2 downstream GSH‐related antioxidant gene expression and activity. In vitro study demonstrated that GSH biosynthesis enzyme GCLc could be an important target of RTA‐408. Furthermore, Nrf2‐deficient mice treated with RTA‐408 had no significant improvement in renal function, histology, ROS production, and GSH‐related gene expression. Thus, by upregulating Nrf2 and its downstream antioxidant genes, RTA‐408 presents a novel and potential approach to renal IRI prevention and therapy.

30 September 2026 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
ZHZhou Hang
Zhou Hang
JZJunqi Zhang
Junqi Zhang
CYChengcheng Yang
Chengcheng Yang
MZMing Zheng
Ming Zheng
ZYZexin Yang
Zexin Yang
MGMin Gu
Min Gu
Background: Iguratimod (IGT) is a small-molecule anti-inflammatory agent that effectively attenuates the progression of antibody-mediated rejection (ABMR). However, the underlying mechanism of action of IGT remains poorly understood. Thus, this study aimed to investigate the mechanism through which IGT regulates macrophage polarization and ABMR. Methods: A mouse model of ABMR was established by performing kidney transplantation after skin graft-induced sensitization. Experimental interventions included neurogenic locus notch homolog protein 4 (NOTCH4) knockout mice and oral administration of IGT. RNA sequencing, quantitative polymerase chain reaction, Western blotting (WB), flow cytometry, and immunofluorescence (IF) staining were performed to investigate M1 macrophage polarization and the Jagged1–NOTCH4 signaling pathway. Results: This study found that IGT significantly reduced M1 macrophage infiltration into renal allografts in a mouse model of ABMR. Transcriptomic sequencing and subsequent biological experiments indicated that IGT may regulate macrophage polarization through the Jagged1–NOTCH4 pathway. Conclusion: M1 macrophage polarization may contribute to the initiation and progression of ABMR following kidney transplantation. IGT attenuates M1 macrophage polarization by inhibiting Jagged1–NOTCH4–Krüppel-like Factor 4 (KLF4) signaling.